drugset / Trial / NCT03718533
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks after the initiation of eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Timeline
- Start
- 2018-12-17
- Primary completion
- 2020-11-03
- Completion
- 2020-11-03
Outcome
Outcome not reported
Stopped: “In the context of COVID-19 pandemic, the benefit / risk ratio of the participation of a patient with pancytopenia could be compromised. The decision of this premature termination was not the consequence of any safety reason inherent to the drug.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 75 mg | Oral |
| Subject | Eltrombopag | Small molecule | 150 mg | Oral |
Indications
No indication recorded.